$0.26
▲ +1.7% Today
as of Aug 5, 16:50 ET
Last 30 days
Recent Press Releases & News
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
Overview
52-week range
$0.24
$0.50
6% of range
Avg surprise (last 3)
+27.8%
Avg reaction (last 2)
-1.7%
0% positive
Latest IV / EM
1408%
EM ±235.3% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.02 | $-0.02 | 0.0% | — | -3.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.02 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.02 | $-0.03 | +33.3% | — | — | earnings |
| Fri Jun 27, 2025 | Mar/2025 | $-0.01 | $-0.02 | +50.0% | — | 0.0% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-0.02 | — | — | — | — | financials |
| Tue Dec 31, 2024 | Dec 2024 | $-0.02 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.03 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.09 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.05 | — | — | — | — | financials |
| Fri Jul 7, 2023 | Mar/2023 | $-0.08 | — | — | — | — | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.02 | -$0.02 | 0.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $317,000 | — | $191,000 | $328,000 | $330,000 | $257,000 | $412,000 | $272,000 |
| Cost of revenue | $262,000 | — | $92,000 | $174,000 | $176,000 | $153,000 | $214,000 | $109,000 |
| Gross profit | $55,000 | — | $99,000 | $154,000 | $154,000 | $104,000 | $198,000 | $163,000 |
| Operating income | $-2M | — | $-3M | $-2M | $-1M | $-2M | $-2M | $-2M |
| Net income | $-2M | — | $-2M | $-2M | $-1M | $-2M | $-2M | $-2M |
| EPS (diluted) | $-0.02 | — | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.03 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $207,000 | $900,000 | $1M | $454,000 | $405,000 | $470,000 | $2M | $2M |
| Inventory | $638,000 | $640,000 | $658,000 | $1M | $1M | $1M | $2M | $2M |
| Total current assets | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $4M |
| Total assets | $9M | $10M | $10M | $8M | $9M | $9M | $10M | $11M |
| Long-term debt | — | — | $132,000 | $133,000 | $134,000 | $134,000 | $135,000 | $136,000 |
| Total liabilities | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M |
| Total equity | $6M | $7M | $8M | $6M | $6M | $6M | $7M | $8M |